|
Viragen and University of Miami to Advance Anti-Cancer Study PLANTATION, Fla., May 12 /PRNewswire-FirstCall/ -- Viragen, Inc. (Amex: VRA) today announced that the Company extended its agreement with the University of Miami and UM/Sylvester Comprehensive Cancer Center to develop a novel form of an immune-enhancing drug (IEP 11) that has shown promise in animal studies by inhibiting tumor growth in a broad range of cancers. The agreement continues to provide Viragen with an option to acquire an exclusive worldwide license to commercialize the technology. "This small peptide molecule called `IEP 11` holds the potential of being a platform technology for the treatment of a broad range of cancers," stated Dr. William H. Stimson, Viragen`s Director of Research (Emeritus). "Initial studies in animals have shown the peptide elicits a powerful immune response against various types of cancer cells. Additionally, those animals that were `IEP 11 immunized` were found to form much smaller tumors or not at all. Our results to date are highly promising and further pre-clinical research studies will be carried out to confirm our preliminary data." Over the next year, Viragen and their University of Miami collaborators plan to carry out a series of pre-clinical studies designed to demonstrate therapeutic efficacy. IEP 11 has already shown to be able to protect against tumor formation in non-human evaluations, so if it also proves efficacious in treatment regimes, the project is expected to move forward toward human clinical evaluations. UM/Sylvester was founded in 1992 to provide comprehensive cancer services and today serves as the hub for cancer-related research, diagnosis and treatment at the University of Miami School of Medicine. UM/Sylvester handles more than 1,100 inpatient admissions annually, performs 2,800 surgical procedures and treats 2,900 new cancer patients. All UM/Sylvester physicians are on the faculty of the University of Miami School of Medicine, South Florida`s only academic medical center. In addition, UM/Sylvester physicians and scientists are engaged in more than 150 clinical trials and receive more than $30 million annually in research grants. UM/Sylvester at Deerfield Beach recently opened to better meet the needs of residents of Broward and Palm Beach Counties. This 10,000 square-foot facility at I-95 and S.W. 10th Street offers appointments with physicians from six cancer specialties, complementary therapies from the Courtelis Center, and education and outreach events. http://www.sylvester.org Fraktal |
|
| aus der Diskussion: | Viragen - aktueller Artikel im Science Magazin |
| Autor (Datum des Eintrages): | Frakt@l (12.05.04 16:03:10) |
| Beitrag: | 116 von 128 (ID:13094368) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |